876 related articles for article (PubMed ID: 26238431)
1. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
[TBL] [Abstract][Full Text] [Related]
2. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
3. Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Miron B; Hoffman-Censits JH; Anari F; O'Neill J; Geynisman DM; Zibelman MR; Kutikov A; Viterbo R; Greenberg RE; Chen D; Lallas CD; Trabulsi EJ; Alpaugh RK; Dulaimi E; Golemis EA; Uzzo R; Ross EA; Plimack ER
Eur Urol Oncol; 2020 Aug; 3(4):544-547. PubMed ID: 32165095
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.
Gil-Jimenez A; van Dorp J; Contreras-Sanz A; van der Vos K; Vis DJ; Braaf L; Broeks A; Kerkhoven R; van Kessel KEM; Ribal MJ; Alcaraz A; Wessels LFA; Seiler R; Wright JL; Mengual L; Boormans J; van Rhijn BWG; Black PC; van der Heijden MS
Eur Urol; 2023 Apr; 83(4):313-317. PubMed ID: 35965206
[TBL] [Abstract][Full Text] [Related]
5. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.
Baras AS; Gandhi N; Munari E; Faraj S; Shultz L; Marchionni L; Schoenberg M; Hahn N; Hoque MO; Berman D; Bivalacqua TJ; Netto G
PLoS One; 2015; 10(7):e0131245. PubMed ID: 26230923
[TBL] [Abstract][Full Text] [Related]
6. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
Groenendijk FH; de Jong J; Fransen van de Putte EE; Michaut M; Schlicker A; Peters D; Velds A; Nieuwland M; van den Heuvel MM; Kerkhoven RM; Wessels LF; Broeks A; van Rhijn BW; Bernards R; van der Heijden MS
Eur Urol; 2016 Mar; 69(3):384-8. PubMed ID: 25636205
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
[TBL] [Abstract][Full Text] [Related]
8. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
Lu YT; Plets M; Morrison G; Cunha AT; Cen SY; Rhie SK; Siegmund KD; Daneshmand S; Quinn DI; Meeks JJ; Lerner SP; Petrylak DP; McConkey D; Flaig TW; Thompson IM; Goldkorn A
Eur Urol Oncol; 2023 Oct; 6(5):516-524. PubMed ID: 37087309
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
Osanto S; Álvarez Gómez de Segura C
Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
[TBL] [Abstract][Full Text] [Related]
10. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
Sjödahl G; Abrahamsson J; Holmsten K; Bernardo C; Chebil G; Eriksson P; Johansson I; Kollberg P; Lindh C; Lövgren K; Marzouka NA; Olsson H; Höglund M; Ullén A; Liedberg F
Eur Urol; 2022 May; 81(5):523-532. PubMed ID: 34782206
[TBL] [Abstract][Full Text] [Related]
11. Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?
Schardt J; Roth B; Seiler R
World J Urol; 2019 Sep; 37(9):1759-1765. PubMed ID: 30392011
[TBL] [Abstract][Full Text] [Related]
12. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
Guancial EA; Kilari D; Xiao GQ; Abu-Farsakh SH; Baran A; Messing EM; Kim ES
PLoS One; 2016; 11(5):e0155503. PubMed ID: 27187160
[TBL] [Abstract][Full Text] [Related]
13. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.
Martini A; Jia R; Ferket BS; Waingankar N; Plimack ER; Crabb SJ; Harshman LC; Yu EY; Powles T; Rosenberg JE; Pal SK; Vaishampayan UN; Necchi A; Wiklund NP; Mehrazin R; Mazumdar M; Sfakianos JP; Galsky MD
Cancer; 2019 Sep; 125(18):3155-3163. PubMed ID: 31150110
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer.
Seah JA; Leibowitz-Amit R; Atenafu EG; Alimohamed N; Knox JJ; Joshua AM; Sridhar SS
Clin Genitourin Cancer; 2015 Aug; 13(4):e229-e233. PubMed ID: 25777682
[TBL] [Abstract][Full Text] [Related]
15. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
Szabados B; Kockx M; Assaf ZJ; van Dam PJ; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; Tyson C; Stanoeva D; Daelemans S; Rombouts M; Mariathasan S; Tea JS; Mousa K; Sharma S; Aleshin A; Banchereau R; Castellano D; Powles T
Eur Urol; 2022 Aug; 82(2):212-222. PubMed ID: 35577646
[TBL] [Abstract][Full Text] [Related]
16. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
[TBL] [Abstract][Full Text] [Related]
17. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
[TBL] [Abstract][Full Text] [Related]
18. Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
Pichler R; Lindner AK; Compérat E; Obrist P; Schäfer G; Todenhöfer T; Horninger W; Culig Z; Untergasser G
Am J Pathol; 2020 Feb; 190(2):442-452. PubMed ID: 31843500
[TBL] [Abstract][Full Text] [Related]
19. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival.
Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A
Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752
[No Abstract] [Full Text] [Related]
20. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
